2022 World Conference on Lung Cancer (ePosters)-EP02.04-004. Time to Surgery After Neoadjuvant Immunotherapy: Not a Day Too Soon

Pdf Summary

A study presented at the 2022 IASLC World Conference on Lung Cancer explored the timing of surgery after neoadjuvant immunotherapy in patients with non-small cell lung cancer (NSCLC). The study included 60 patients who were randomly assigned to receive neoadjuvant durvalumab alone or combined with sub-ablative focal stereotactic radiation. The patients were divided into two groups based on the median time to surgical resection: Group A (operated on in 16 days or less) and Group B (operated on in 17 days or more). <br /><br />The results showed that lung resection after neoadjuvant durvalumab with or without radiation can be performed as early as two weeks after the end of neoadjuvant therapy without compromising the rate of pathological response or the depth of response. Traditionally, surgery after neoadjuvant treatment for NSCLC has been performed 3 to 4 weeks after chemotherapy or 4 to 8 weeks after chemoradiation. However, it is unclear if the same time delays are applicable to surgery after neoadjuvant immunotherapy.<br /><br />The study found that there was no difference in the immune gene expression profiles of resected tumors between the two groups. Additionally, there was no difference in the median depth of pathologic response, with nine patients having a major pathological response in each group.<br /><br />Overall, this study suggests that surgery after neoadjuvant immunotherapy can be performed earlier than traditionally recommended without compromising outcomes. The findings have implications for the timing of surgical resection in patients receiving neoadjuvant immunotherapy for NSCLC.

Asset Subtitle

Nathan Mynard

Meta Tag

Speaker Nathan Mynard

Topic Early Stage Non-small Cell Lung Cancer - Systemic Therapy

Keywords

IASLC World Conference on Lung Cancer

neoadjuvant immunotherapy

non-small cell lung cancer

surgery timing

durvalumab

sub-ablative focal stereotactic radiation

surgical resection

pathological response

immune gene expression profiles

timing of surgical resection